[Cytokine therapy of metastatic renal cell carcinoma].
Cytokine therapy of metastatic renal cell carcinoma reveals a remission rate of about 25% regarding to the different patients selection criteria, i.e. age, performance status, site of metastasis, tumour load. Remission is not correlated to patient's survival. Adjuvant or neoadjuvant immunotherapy is not a treatment option. Nephrectomy has no influence on distant metastases and should be limited to symptomatic primary tumours. In conclusion, cytokine therapy is not a standard treatment. Its value has to be evaluated in randomized trials.
Otto
T
T
Urologische Klinik, Universitätsklinkum, GHS, Essen.
Goepel
M
M
Luboldt
H J
HJ
Rübben
H
H
D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D009362:Neoplasm Metastasis; D011379:Prognosis; D011994:Recombinant Proteins; D015996:Survival Rate
D016207:Cytokines; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma